Literature DB >> 17506609

Hepatitis B virus genotype distribution and its lamivudine-resistant mutants in HIV-coinfected patients with chronic and occult hepatitis B.

J Quarleri1, F Moretti, M B Bouzas, N Laufer, M Gómez Carrillo, S Fernández Giuliano, H Pérez, P Cahn, H Salomon.   

Abstract

Hepatitis B virus (HBV) genotypes were examined in HIV-infected patients with chronic and occult HBV infection. From a total population of 593 HIV-infected patients, 22 individuals (prevalence 3.7%) were found to be HBsAg while 72 (12.1%) were found to be anti-HBc alone. From them, 20 and 4 were HBV DNA positive, respectively. These last four patients are therefore considered to be HBV infected in an occult form. The genotypes could be determined in all 24 HBV-infected patients. HBV-A was the most common (20/24; 83.3%), followed by HBV-D (2/24; 8.3%) and HBV-F (1/24; 4.2%). The remaining sample exhibited mixed infection involving genotypes A and D as pure ones, thus also forming part of three intergenotypic recombinant forms exhibiting different mosaic S gene patterns. The sexual route of transmission was predominant among HBV genotype A-infected patients. Among the 24 HBV DNA-positive patients, point mutations related to lamivudine resistance were found in four strains. These viral strains showed a methionine-to-valine substitution at codon 204 (rtM204V) in association with an upstream B-domain change at rtL180M. Additionally, two of them exhibited the additional rtV173L mutation. The value of HBV molecular monitoring including both HBV viral genomic characterization and genotypic resistance profile in HIV-HBV-coinfected individuals is discussed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17506609      PMCID: PMC2894418          DOI: 10.1089/aid.2006.0172

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  28 in total

Review 1.  Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region.

Authors:  L J Stuyver; S A Locarnini; A Lok; D D Richman; W F Carman; J L Dienstag; R F Schinazi
Journal:  Hepatology       Date:  2001-03       Impact factor: 17.425

2.  Primary infection with a lamivudine-resistant hepatitis B virus.

Authors:  Vincent Thibault; Camille Aubron-Olivier; Henri Agut; Christine Katlama
Journal:  AIDS       Date:  2002-01-04       Impact factor: 4.177

3.  Is hepatitis B virus subtype testing useful in predicting virological response and resistance to lamivudine?

Authors:  Maria Buti; Montserrat Cotrina; Auristela Valdes; Rosendo Jardi; Francisco Rodriguez-Frias; Rafael Esteban
Journal:  J Hepatol       Date:  2002-03       Impact factor: 25.083

Review 4.  Management of hepatitis B: 2000--summary of a workshop.

Authors:  A S Lok; E J Heathcote; J H Hoofnagle
Journal:  Gastroenterology       Date:  2001-06       Impact factor: 22.682

5.  Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.

Authors:  N W Leung; C L Lai; T T Chang; R Guan; C M Lee; K Y Ng; S G Lim; P C Wu; J C Dent; S Edmundson; L D Condreay; R N Chien
Journal:  Hepatology       Date:  2001-06       Impact factor: 17.425

Review 6.  Hepatitis B virus co-infection in human immunodeficiency virus-infected subjects.

Authors:  Massimo Puoti; Monica Airoldi; Raffaele Bruno; Barbara Zanini; Angiola Spinetti; Chiara Pezzoli; Andrea Patroni; Francesco Castelli; Paolo Sacchi; Gaetano Filice; Giampiero Carosi
Journal:  AIDS Rev       Date:  2002 Jan-Mar       Impact factor: 2.500

7.  Prevalence of hepatitis viruses in an anti-human immunodeficiency virus-positive population from Argentina. A multicentre study.

Authors:  H Fainboim; J González; E Fassio; A Martínez; L Otegui; M Eposto; P Cahn; R Marino; G Landeira; G Suaya; E Gancedo; R Castro; L Brajterman; H Laplumé
Journal:  J Viral Hepat       Date:  1999-01       Impact factor: 3.728

8.  The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance.

Authors:  S K Ono; N Kato; Y Shiratori; J Kato; T Goto; R F Schinazi; F J Carrilho; M Omata
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

9.  High-throughput quantitative analysis of hepatitis B virus DNA in serum using the TaqMan fluorogenic detection system.

Authors:  K R Loeb; K R Jerome; J Goddard; M Huang; A Cent; L Corey
Journal:  Hepatology       Date:  2000-09       Impact factor: 17.425

10.  20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw.

Authors:  B Zöllner; J Petersen; M Schröter; R Laufs; V Schoder; H H Feucht
Journal:  Lancet       Date:  2001-03-24       Impact factor: 79.321

View more
  10 in total

1.  Prevalence and characteristics of hepatitis B and C virus infections in treatment-naïve HIV-infected patients.

Authors:  Stefan Reuter; Mark Oette; Frank Clemens Wilhelm; Bastian Beggel; Rolf Kaiser; Melanie Balduin; Finja Schweitzer; Jens Verheyen; Ortwin Adams; Thomas Lengauer; Gerd Fätkenheuer; Herbert Pfister; Dieter Häussinger
Journal:  Med Microbiol Immunol       Date:  2010-09-19       Impact factor: 3.402

2.  HBsAg, HBeAg and HBV DNA level changes and precore/basal core promoter mutations in the natural history of chronic hepatitis B in Indonesian patients.

Authors:  Meta Dewi Thedja; Susan Irawati Ie; Alida Roswita Harahap; Korri Elvanita El-Khobar; Martono Roni; David Handojo Muljono
Journal:  Hepatol Int       Date:  2013-05-23       Impact factor: 6.047

3.  Outbreak of infections by hepatitis B virus genotype A and transmission of genetic drug resistance in patients coinfected with HIV-1 in Japan.

Authors:  Seiichiro Fujisaki; Yoshiyuki Yokomaku; Teiichiro Shiino; Tomohiko Koibuchi; Junko Hattori; Shiro Ibe; Yasumasa Iwatani; Aikichi Iwamoto; Takuma Shirasaka; Motohiro Hamaguchi; Wataru Sugiura
Journal:  J Clin Microbiol       Date:  2011-01-19       Impact factor: 5.948

4.  Drug-resistant and immune-escape hepatitis B virus mutants, occult hepatitis B infection and coinfections in public hospital patients from Argentina.

Authors:  Cecilia María Delfino; Marianela Giorgio; Gabriela García; Silvia Sánchez Puch; Estela Outon; Verónica Lidia Mathet
Journal:  Virus Genes       Date:  2021-06-06       Impact factor: 2.332

Review 5.  Clinical impact of occult hepatitis B virus infection in immunosuppressed patients.

Authors:  Evangelista Sagnelli; Mariantonietta Pisaturo; Salvatore Martini; Pietro Filippini; Caterina Sagnelli; Nicola Coppola
Journal:  World J Hepatol       Date:  2014-06-27

6.  Genotyping and molecular characterization of hepatitis B virus from human immunodeficiency virus-infected individuals in southern Africa.

Authors:  Euphodia Makondo; Trevor G Bell; Anna Kramvis
Journal:  PLoS One       Date:  2012-09-28       Impact factor: 3.240

7.  Occult hepatitis B virus infection: A major concern in HIV-infected patients: Occult HBV in HIV.

Authors:  Amitis Ramezani; Mohammad Banifazl; Minoo Mohraz; Mehrnaz Rasoolinejad; Arezoo Aghakhani
Journal:  Hepat Mon       Date:  2011-01       Impact factor: 0.660

8.  Epidemiology, risk factors and genotypes of HBV in HIV-infected patients in the northeast region of Colombia: high prevalence of occult hepatitis B and F3 subgenotype dominance.

Authors:  Henry Bautista-Amorocho; Yeny Zulay Castellanos-Domínguez; Laura Andrea Rodríguez-Villamizar; Sindi Alejandra Velandia-Cruz; Jeysson Andrey Becerra-Peña; Ana Elvira Farfán-García
Journal:  PLoS One       Date:  2014-12-02       Impact factor: 3.240

9.  Prevalence of hepatitis B in people living with HIV/AIDS in Latin America and the Caribbean: a systematic review and meta-analysis.

Authors:  Fatima Mitiko Tengan; Edson Abdala; Marisa Nascimento; Wanderley Marques Bernardo; Antonio Alci Barone
Journal:  BMC Infect Dis       Date:  2017-08-24       Impact factor: 3.090

Review 10.  Naturally occurring hepatitis B virus reverse transcriptase mutations related to potential antiviral drug resistance and liver disease progression.

Authors:  Yu-Min Choi; So-Young Lee; Bum-Joon Kim
Journal:  World J Gastroenterol       Date:  2018-04-28       Impact factor: 5.742

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.